Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Investor Update - 11th October
Following the release of our 2022 Annual Report, the company is pleased to announce that it will be providing a live presentation via the Investor Meet Company platform on 11th Oct 2022 at 11:00am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can register with Investor Meet Company for free and add to meet MGC PHARMACEUTICALS LIMITED via:
https://www.investormeetcompany.com/mgc-pharmaceuticals-limited/register-investor
Best of luck with your future investments Oz. I’m going down with the ship unless we miss the proverbial iceberg and make it to New York city baby.
A sook, how rude. Back to MGC, do you guys see any green shoots …AMC, new FD, new commercial director etc? All I see is Sciensus getting slated.
What a £&@“house. Typical keyboard warrior. Time to get up Wolf, mums put your coco pops on the table.
Hahahaha. If it means so much to you, I’ll happily say that to your face.
Thanks for the offer but life is busy and I don’t have time to meet people, without a purpose. If you have an sensible agenda and live in the south I will consider it.
Calm down keyboard warrior. Stick to your GB news and ‘snowflake’ narrative.
They guy called wolf of Wall Street is being deliberately combative and obtuse so do not lower yourself to his level. I am invested here and as I have said in the past until we see revenue increasing and losses reducing the sp won’t move materially. We do need to see positive news on Malta and the AMC deal this side of Christmas to show we are headed in the right direction however.
I’m just telling you how it is. You knew when investing this was a higher risk play and in turn with the potential upside there’s the potential down. We’re not investing in a bluechip are we. The amount you have invested is irrelevance and personal. But the facts remain the facts and we all make out bed!
They are having a rebranding exercise. Go and have chamomile tea, go for a walk or something. This isn’t going to move until revenue rises and they head towards profitability. Findings in place so either stay on the rollercoaster or I’d advise get off if it’s causing you too much discomfort.
Page 20 of the last financial accounts. The 1m is only part of the conditions and the options are also contingent on share price movement. More world is flat believers here than anywhere else!
Remuneration policy
The remuneration policy of the Company was that each director entered into a service agreement with the Group on a salary per annum, with Roby Zomer, Victor Bolduev and Pavel Kobzev also earning a salary under Graft Polymer d.o.o. Since re-admission subsequent to period-end, a remuneration committee has been appointed to reassess an appropriate level of Directors’ remuneration and it is envisaged that the remuneration policy will assist to attract, retain and motive Executive Directors and senior management of a high calibre with a view to encouraging commitment to the development of the Company and for long term enhancement of shareholder value. The Board believes that share ownership by Directors strengthens the link between their personal interests and those of shareholders.
The current Directors’ remuneration comprises a basic fee and at period end, there was no bonus of long-term incentive plan in operation for Directors.
Subsequent to period end and upon admission to the LSE, the directors were granted options over Ordinary Shares pursuant to a Share Option Scheme, of which are detailed below:
Director
Roby Zomer Victor Bolduev Pavel Kobzev Alex Brooks Yifat Steuer
Number of Ordinary Share under option
1,700,000 2,200,000 1,600,000 1,000,000 1,673,611
Weighted Average Exercise Price per Ordinary Share £
£0.001 £0.001 £0.001 £0.001 £0.001
One third of the options will vest on satisfaction of the first milestone and two thirds will vest on the satisfaction of the second milestone. The milestones are as follows:
l first milestone:
o the Company’s share price reaching appreciation of 125 per cent. of the Issue Price based on a 15-day
volume weighted average price in the period 12 months from the date of Admission; and
o the generation by the Group of revenue in a twelve-month period of EURO1,000,000 or more.
l second milestone:
o the Company’s share price reaching appreciation of 150 per cent. based on a 15-day volume weighted
average price in the period 24 months from Admission; and
o the generation by the Group of revenue in a twelve-month period of EURO5,000,000 or more.
I think the MGC board are on a sabbatical - Thailand’s lovely this time of the year. . Possibly returning to work in the next few months! Maybe when they’re back we can expect some form of update. In the mean time, don’t spill your piña colada’s boys!!
The Senate is the problem. Full of old timers.
Now time to wake up, stop hallucinating. Any buy out would only happen once there’s an approved product, FDA etc. This is a long way off. Similar to GW and Jazz after the approval of epidiolex.
Ah yes a nice plug for Alla Zomer’s company, Extrax! That’s Roby’s wife for any newbies to this page. I think they’ve got this one straight out of the ‘how to **** your investors off’ book.
You may want to look at who wrote the Canaccord report and gave the ‘broker rating’ - Alex Brooks. An Alex Brooks sits on the board of Graft Polymer. Make of it what you will.
Chaps, I mentioned Sputnik several months ago and it didn’t seem at the time anyone really had any information on the link. Since then and in the last quarterly there was a £ 180k payment made from MGC to this entity owned by Roby Zomer and Brett M for advisory services for the fund raise in Dec ‘21. I’m not in mood to cast aspersions about this however if anyone can give a clear and educated answer as to why this payment could legitimately be made, then I would very interest to hear from someone more knowledgeable than me.
Just sold off a few pheasants and bottles of Krug Clos d'Ambonnay Blanc de Noirs Brut to buy some more MGC shares on Monday.
Why anyone would buy in at c.6p and sell at 2p after 10 months is beyond me. Madness.